Boothbay Fund Management LLC Buys 5,955 Shares of Abbott Laboratories (NYSE:ABT)

Boothbay Fund Management LLC increased its position in Abbott Laboratories (NYSE:ABT - Free Report) by 122.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,818 shares of the healthcare product maker's stock after purchasing an additional 5,955 shares during the period. Boothbay Fund Management LLC's holdings in Abbott Laboratories were worth $1,224,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Morse Asset Management Inc bought a new position in shares of Abbott Laboratories in the 3rd quarter worth about $380,000. Tudor Financial Inc. bought a new position in Abbott Laboratories in the third quarter worth about $302,000. Anchor Investment Management LLC boosted its stake in Abbott Laboratories by 2.9% in the third quarter. Anchor Investment Management LLC now owns 54,237 shares of the healthcare product maker's stock valued at $6,184,000 after acquiring an additional 1,509 shares during the period. Fulcrum Equity Management bought a new position in shares of Abbott Laboratories during the third quarter valued at approximately $239,000. Finally, Wilmington Savings Fund Society FSB grew its stake in Abbott Laboratories by 32.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 332,189 shares of the healthcare product maker's stock worth $37,873,000 after buying an additional 81,669 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Price Performance

Shares of NYSE ABT traded up $0.21 during trading on Thursday, hitting $130.96. The company had a trading volume of 6,764,691 shares, compared to its average volume of 6,092,744. The company has a market cap of $227.12 billion, a P/E ratio of 17.12, a PEG ratio of 2.52 and a beta of 0.80. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The business's 50-day moving average is $130.35 and its 200 day moving average is $122.71. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating the consensus estimate of $1.07 by $0.02. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. Equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.80%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories's payout ratio is 30.61%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Raymond James boosted their price target on shares of Abbott Laboratories from $132.00 to $142.00 and gave the company an "outperform" rating in a report on Thursday, April 17th. Morgan Stanley raised their price target on shares of Abbott Laboratories from $117.00 to $127.00 and gave the company an "equal weight" rating in a research note on Thursday, April 17th. Barclays boosted their price objective on Abbott Laboratories from $158.00 to $159.00 and gave the stock an "overweight" rating in a research report on Thursday, April 17th. Citigroup lifted their target price on Abbott Laboratories from $135.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Finally, Piper Sandler reissued an "overweight" rating and issued a $145.00 price target (up previously from $133.00) on shares of Abbott Laboratories in a research note on Thursday, April 17th. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $142.59.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Andrea F. Wainer sold 949 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $131,123.33. Following the transaction, the executive vice president now directly owns 74,381 shares in the company, valued at $10,277,222.77. The trade was a 1.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Eric Shroff sold 562 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $77,651.54. Following the sale, the senior vice president now owns 31,970 shares of the company's stock, valued at approximately $4,417,294.90. This represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 92,678 shares of company stock valued at $12,408,743 in the last three months. 0.46% of the stock is currently owned by company insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.